Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.75 |
| ▸ | TP53 | P04637 | 7/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | TLR4 | O00206 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896219 | 0.93 | LMNA (0.82) | LMNATP53MEN1KMT2APOLB | |
| SCHEMBL16896049 | 0.93 | LMNA (0.85) | LMNATP53MEN1KMT2APOLB | |
| SCHEMBL16896094 | 0.92 | LMNA (0.87) | LMNATP53MEN1KMT2APOLB | |
| SCHEMBL16896100 | 0.92 | LMNA (0.87) | LMNATP53MEN1KMT2APOLB | |
| SCHEMBL16896209 | 0.92 | LMNA (0.87) | LMNATP53MEN1KMT2APOLB | |
| SCHEMBL19507992 | 0.90 | LMNA (0.73) | LMNATP53MEN1KMT2APOLB | |
| SCHEMBL19507016 | 0.84 | LMNA (0.65) | LMNATP53MEN1KMT2APOLB | |
| SCHEMBL16896106 | 0.83 | TP53 (0.81) | LMNATP53MEN1KMT2APOLB | |
| SCHEMBL16903565 | 0.82 | MAPT (0.80) | LMNATP53MAPT | |
| SCHEMBL16896188 | 0.82 | POLB (0.76) | LMNATP53KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505768-B2 | Compositions and methods for modulating TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | TLR4, TLR3, TLR6 | LMNA 1484/4885TP53 1455/4885MEN1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.